{"id":"lonazolac","rwe":[{"pmid":"40819363","year":"2025","title":"Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling, in vitro and in vivo anti-inflammatory activities.","finding":"","journal":"Future medicinal chemistry","studyType":"Clinical Study"},{"pmid":"40405028","year":"2026","title":"Novel pyrazole carboxylate derivatives as lonazolac bioisosteres with selective COX-2 inhibition: design, synthesis and anti-inflammatory activity.","finding":"","journal":"Molecular diversity","studyType":"Clinical Study"},{"pmid":"39014146","year":"2025","title":"Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation.","finding":"","journal":"Molecular diversity","studyType":"Clinical Study"},{"pmid":"38828869","year":"2024","title":"Pyrazoles as Anti-inflammatory and Analgesic Agents: In-vivo and In-silico Studies.","finding":"","journal":"Anti-inflammatory & anti-allergy agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"36278313","year":"2022","title":"Ag(2)O-Induced Regioselective Huisgen Cycloaddition for the Synthesis of Fully Substituted Pyrazoles as Potential Anticancer Agents.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"lonazolac","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin E synthase","category":"target"},{"label":"PTGES","category":"gene"},{"label":"M01AB09","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lonazolac","lonazolac calcium"],"offLabel":[],"synonyms":["lonazolac","lonazolac calcium"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Prostaglandin E synthase","targets":[{"gene":"PTGES","source":"DrugCentral","target":"Prostaglandin E synthase","protein":"Prostaglandin E synthase"}],"modality":"Small Molecule","drugClass":"lonazolac","explanation":"Prostaglandins are hormone-like substances that can cause pain and inflammation. By blocking the enzyme that makes prostaglandins, LONAZOLAC may help reduce pain and inflammation. This can be beneficial for people with conditions such as arthritis or other inflammatory diseases.","oneSentence":"LONAZOLAC works by inhibiting the enzyme Prostaglandin E synthase, which plays a role in the production of prostaglandins.","technicalDetail":"LONAZOLAC specifically inhibits the activity of Prostaglandin E synthase-2 (PGES-2), a key enzyme involved in the production of prostaglandin E2 (PGE2), a potent pro-inflammatory mediator."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1597","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LONAZOLAC","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:23:55.848299","biosimilars":[],"competitors":[{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sulindac","drugSlug":"sulindac","fdaApproval":"1978-09-27","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolmetin","drugSlug":"tolmetin","fdaApproval":"1976-03-24","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"diclofenac","drugSlug":"diclofenac","fdaApproval":"1988-07-28","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"etodolac","drugSlug":"etodolac","fdaApproval":"1991-01-31","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketorolac","drugSlug":"ketorolac","fdaApproval":"1989-11-30","patentExpiry":"Nov 24, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aceclofenac","drugSlug":"aceclofenac","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lonazolac","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-class"},{"drugId":"sulindac","brandName":"sulindac","genericName":"sulindac","approvalYear":"1978","relationship":"same-class"},{"drugId":"tolmetin","brandName":"tolmetin","genericName":"tolmetin","approvalYear":"1976","relationship":"same-class"},{"drugId":"diclofenac","brandName":"diclofenac","genericName":"diclofenac","approvalYear":"1988","relationship":"same-class"},{"drugId":"etodolac","brandName":"etodolac","genericName":"etodolac","approvalYear":"1991","relationship":"same-class"},{"drugId":"ketorolac","brandName":"ketorolac","genericName":"ketorolac","approvalYear":"1989","relationship":"same-class"},{"drugId":"aceclofenac","brandName":"aceclofenac","genericName":"aceclofenac","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005986","UNII":"13097143QI","CHEBI":"CHEBI:76164","INN_ID":"3829","RXNORM":"28876","UMLSCUI":"C0065166","ChEMBL_ID":"CHEMBL1334692","KEGG_DRUG":"D07265","DRUGBANK_ID":"DB13432","PUBCHEM_CID":"68706","SECONDARY_CAS_RN":"75821-71-5","MESH_SUPPLEMENTAL_RECORD_UI":"C017472"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":50,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AB09","allCodes":["M01AB09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug","pmid":"40819363","title":"Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling, in vitro and in vivo anti-inflammatory activities.","journal":"Future medicinal chemistry"},{"date":"2026 Feb","pmid":"40405028","title":"Novel pyrazole carboxylate derivatives as lonazolac bioisosteres with selective COX-2 inhibition: design, synthesis and anti-inflammatory activity.","journal":"Molecular diversity"},{"date":"2025 Apr","pmid":"39014146","title":"Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation.","journal":"Molecular diversity"},{"date":"2024","pmid":"38828869","title":"Pyrazoles as Anti-inflammatory and Analgesic Agents: In-vivo and In-silico Studies.","journal":"Anti-inflammatory & anti-allergy agents in medicinal chemistry"},{"date":"2022 Nov 4","pmid":"36278313","title":"Ag(2)O-Induced Regioselective Huisgen Cycloaddition for the Synthesis of Fully Substituted Pyrazoles as Potential Anticancer Agents.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LONAZOLAC","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LONAZOLAC is a small molecule drug that targets Prostaglandin E synthase. It belongs to the lonazolac class and its mechanism of action is not well-documented. There is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand its clinical utility and safety profile. As a result, it is not possible to provide a comprehensive summary of LONAZOLAC at this time.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}